Navigation Links
Talyst Announces New Automated Medication Packager
Date:6/26/2012

KIRKLAND, Wash., June 26, 2012 /PRNewswire/ -- Talyst, a leader in pharmacy automation, announces its newest AutoPack®, which automates packaging for oral solid medications.

The new AutoPack integrates with existing pharmacy operations and provides unit-or multi-dose oral solid medication packaging. The packager features an Auto Canister that provides automatic dispensing for half dose tablets, infrequently used tablets or tablets with special shapes.

"Our new AutoPack complements our existing oral packager suite," said Carla Corkern, Chief Executive Officer at Talyst. "It's another tool to support hospitals with their barcode initiatives."

Combining Talyst's AutoPack with their AutoLabel ensures that virtually 100% of the medications leaving pharmacies are scan-ready at the bedside. The barcoding technology is aligned with the Centers for Medicaid & Medicaid Services' (CMS) recent stage 2 "meaningful use" criteria ruled in the Health Information Technology for Economic and Clinical Health (HITECH) Act.

About Talyst

Talyst is a leader in pharmacy automation and engineers the safer pharmacy. Our solutions provide enterprise-wide medication management across your entire health system to offer greater inventory control, enhanced workflow efficiency, and improved patient safety. As of 2012, Talyst has installed automated systems in more than 600 integrated healthcare systems, acute-care hospitals, long-term care facilities, and correctional institutions. We offer a powerful software platform with a suite of hardware components to meet your specific needs. Follow us on Twitter @Talyst_Inc or visit us at, www.talyst.com.


'/>"/>
SOURCE Talyst
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Thermal Gradient Announces Manufacture of Next Generation DNA Testing Device
2. PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
3. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
4. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
5. Shire Announces that the US Food and Drug Administration has Responded to its Citizen Petition for Adderall XR and has Approved One Abbreviated New Drug Application for Generic Adderall XR
6. ERT Announces Stockholder Approval of Merger
7. Biodel Announces $18.5 Million Private Placement
8. BioElectronics Corporation Announces Indian Distributors Ecommerce Website
9. Marken Announces Global Advisory Board
10. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
11. Generex Announces Results of Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, 2015 /PRNewswire/ ... medical device company that is providing innovative evidence-based solutions ... it has commenced an underwritten public offering of its ... by Nevro and 2,459,175 shares to be sold by ... grant the underwriters a 30-day option to purchase up ...
(Date:6/1/2015)... MENLO PARK, Calif. , June 1, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, today announced ... trial of  VAL-083  (dianhydrogalactitol) in patients with refractory ... form of human brain cancer. Results ...
(Date:6/1/2015)... CEFALY Technology , the creators of ... authorized for use prior to the onset of migraine ... trial showing that the Cefaly device returns normal metabolic ... patients, namely the orbitofrontal cortex and rostral cingulate. ... an imaging test of the brain, used a radioactive substance called a ...
Breaking Medicine Technology:Nevro Announces Proposed Public Offering of Common Stock 2Nevro Announces Proposed Public Offering of Common Stock 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 2DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 3DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 4DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 5DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 6DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 7DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data on VAL-083 in Refractory Glioblastoma Multiforme (GBM) at ASCO 8New Study Shows CEFALY Returns Normal Metabolic Activity to Brain Areas in Migraine Patients 2
... Clinical Development for the Treatment of ... Opioid Bowel Dysfunction, ... presented positive results this week from Phase,1 and preclinical studies of ... in Las Vegas, Nevada. NKTR-118 is,Nektar,s proprietary oral therapy being studied ...
... physician leading clinical trials, FREEPORT, N.Y., ... in treating facial bruising from injectable cosmetic,treatments ... known for,treating under-eye circles. Pinoxide is ... (BMTd),created by AGI Dermatics and formulated in ...
Cached Medicine Technology:Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 2Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 3Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 4Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting 5Promising Results in Treating Facial Bruising From Injectables 2
(Date:6/1/2015)... Carson Energy also announced they have ... transactions. AdvantaIRA Trust, LLC is the country’s largest self-directed ... fund positions using IRA’s does 2 things:, 1. It ... even if there current cash position will not allow ... for Carson and their investors to be able to ...
(Date:6/1/2015)... 01, 2015 The federal court overseeing ... amended the Case Management Order governing case selection for ... Amended Order which was issued in the U.S. ... 2015, directs the parties to submit a Proposed Case ... that outlines parameters and the process for selecting AbbVie-only ...
(Date:6/1/2015)... June 01, 2015 Atagi Plastic Surgery ... been named an Ultherapy® Ultra Treatment Provider ... and Skin Aesthetics is one of only six practices ... premier treatment provider. , Atagi Plastic Surgery and ... Denver area has led the practice to earn the ...
(Date:6/1/2015)... Washington, D.C. (PRWEB) June 01, 2015 Linda ... tired and had an irregular heartbeat. At first she thought ... soon found out it was much more than that. After ... valve disease. Linda admitted she felt afraid about what might ... as five million Americans are diagnosed with valve disease each ...
(Date:6/1/2015)... June 01, 2015 On May 14, ... center hosted the Cherry Creek Chamber of Commerce ... clinic. Urgent care centers typically do not offer primary ... AFC/Doctors Express Cherry Creek Urgent Care staff to schedule ... , From 5:30 to 7:30 p.m. the center hosted ...
Breaking Medicine News(10 mins):Health News:Carson Energy Brings Oil Wells To IRAs 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 3Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 4Health News:Atagi Plastic Surgery and Skin Aesthetics Named Ultherapy® Ultra Treatment Provider 2Health News:A New Online Resource for Those Living with Heart Valve Disease 2Health News:A New Online Resource for Those Living with Heart Valve Disease 3Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2
... of Michigan scientists have found that a deficiency in a key ... type of adult brain cancer. The study, conducted in mice that ... and a way to screen for the disease early. Appearing ... in mice show for the first time that:, Glioblastoma, the ...
... A closer look at regulatory and clinical concerns with ... to an educational advisory by the International Society for ... issue of The Journal of Heart and Lung ... Thoracic transplant patients ...
... Georgia to use a new, cutting edge diagnostic ... outcomes. , , WOBURN, Mass., and VEDBAEK, Denmark, ... Medical Center in Savannah, Georgia has implemented AdvanDx,s PNA FISH(R) ... than conventional methods to help their physicians, pharmacists and nurses ...
... addresses limitations of current randomized trials , , ... Inc . highlighted recent clinical panel presentations underscoring ... for treating asthma in adults and children. The company ... to mixed results in some randomized trials of eNO-guided ...
... Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced ... has approved the design of pivotal, Phase 2b/3 clinical ... drug for the acute treatment of patients with paroxysmal ... process. , , ATPace(TM) is a novel ...
... China, June 2 /PRNewswire-Asia/ -- China Nepstar Chain Drugstore,Ltd. ... "Company"), the largest drugstore,chain in China based on the ... Mr. Jason (Xinghua) Wu as the Chief Operating,Officer. ... overseeing,procurement, logistics, store development and store operations. He ...
Cached Medicine News:Health News:Most common brain cancer may start in neural stem cells 2Health News:Most common brain cancer may start in neural stem cells 3Health News:Most common brain cancer may start in neural stem cells 4Health News:More stringent evaluation on the use of generic medications in thoracic transplantation 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 2Health News:Memorial University Medical Center (MUMC) Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 3Health News:Clinical Utility of Exhaled Nitric Oxide Highlighted By American Thoracic Society Panel 2Health News:Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM) 2Health News:Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM) 3Health News:Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM) 4Health News:China Nepstar Chain Drugstore Appoints Chief Operating Officer 2Health News:China Nepstar Chain Drugstore Appoints Chief Operating Officer 3
... CTi Wrist OTS is an off-the-shelf wrist orthotic designed ... of 3 pre-set ranges-of-motion (20°,35° and 50°). , ... sprains with TFCC tear-triangular fibrocartilage complex , ... nonunion , Partial tendon rupture , ...
... The CTi Wrist Static is a solid, one-piece ... in a stable, neutral position. , ,Indications: , ... TFCC tear-triangular fibrocartilage complex , Coles fracture ... , Partial tendon rupture , ORIF ...
The Universal Wrist/Forearm Splint is ideal for post-surgical immobilization, post-fracture casting, wrist sprains and strains....
... wrist orthotic designed to limit the extension of the ... ,Indications: , Wrist reconstruction , Wrist ... Coles fracture - distal radius , Scaphoid ... ORIF - Open reduction and internal fixation for ...
Medicine Products: